AU
UK
CA
NZ
IND
US
Ceva, Inc. (NASDAQ:CEVA) currently holds a“Moderate Buy”consensus rating from six research firms that cover the stock. Marketbeat Ratings notes thatone firm issued a sell recommendation, whilefive firms issued buy recommendations. These firms updated their coverage during the past year. Theaverage 12-month target priceamong analysts …
MarketBeat Ratings reports thatargenx SE (NASDAQ:ARGX)holds anaverage rating of “Moderate Buy.”This assessment comes fromtwenty-four brokeragescurrently following the biotechnology company. Of these:
Regencell Bioscience Holdings Ltd (NASDAQ:RGC) closed atUSD 16.07on December 05, reflecting a rise of17.0c (1.1%)from the prior session. The move compared with theNASDAQ-100, which added85.5 points (0.3%)during the day. The stock’s relative price increase of0.7%against the index placed it ahead of the broader benchmark …
As the trading week wrapped up, the tech-drivenNasdaq 100showcased firm resilience, shrugging off recent turbulence and closing on an optimistic note. With a key inflation reading finally released, traders set aside political noise and lingering macro uncertainty, redirecting their full attention to the Federal …
Gilead Sciences (NASDAQ:GILD), through its Kitesubsidiary, presented new data reinforcing the performance and consistency of its CAR T-cell therapy, Yescarta, in patients with relapsed or refractory large B-cell lymphoma (R/R LBCL). The analysis combined four-year outcomes from the Phase 3 ZUMA-7 trial and two-year …
Ascentage Pharma Group International (NASDAQ:AAPG) presented new clinical results from its Phase Ib/II trial evaluating Lisaftoclax (APG-2575) in combination with azacitidine during the 67th American Society of Hematology Annual Meeting. The trial focused on patients with newly diagnosed or prior venetoclax-exposed myeloid malignancies, including …
HUTCHMED Limited(NASDAQ:HCM)announced renewed inclusion of three key oncology therapies—ELUNATE®, ORPATHYS® and SULANDA®—in China’s updated National Reimbursement Drug List (NRDL), effective January 1, 2026. The renewed listing follows a contract renewal with the National Healthcare Security Administration, reflecting continued recognition of these therapies within China’s …
Structure Therapeutics (NASDAQ:GPCR) announced that it will publish topline results from its ACCESS clinical program evaluating aleniglipron, the company’s once-daily oral GLP-1 receptor agonist for obesity, before the market opens on December 8, 2025. Anticipation is high as the company works to advance an …
Immix Biopharma (NASDAQ:IMMX) announced promising Phase 2 clinical results for its sterically optimized CAR-T candidate NXC-201 during an oral presentation at ASH 2025. Led by Dr. Heather Landau of Memorial Sloan Kettering Cancer Center, the data highlighted a 75% complete response rate in relapsed/refractory …
Eli Lilly and Company (NYSE:LLY) has released pivotal data from the Phase 3 BRUIN CLL-314 trial, marking the first randomized head-to-head comparison between covalent and non-covalent BTK inhibitors in chronic lymphocytic leukemia and small lymphocytic lymphoma. Jaypirca (pirtobrutinib), Lilly’s highly selective, reversible BTK inhibitor, …
Please wait processing your request...